Position in LXEO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,932,174
-$3,830,326 QoQ
Shares Held
1,489,189
-20.6% QoQ
Ownership
1.82%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#20
of 141 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LXEO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Avoro Capital Advisors LLC holds $9,631,167,263 across 25 Biotechnology names. LXEO ranks #25 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
5,111,111 | $1,363,235,525 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
2,888,888 | $1,073,713,002 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,833,333 | $984,408,154 | |
| 4 | ARGX |
Argenx SE
|
1,000,000 | $927,770,000 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
11,355,555 | $925,591,288 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
7,474,747 | $857,129,238 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
2,297,000 | $430,182,160 | |
| 8 | CYTK |
Cytokinetics Inc
|
4,999,999 | $425,949,914 |
All Filings in LXEO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,932,174 | 1,489,189 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $10,762,500 | 1,875,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $32,769,000 | 3,300,000 | Shares | Sole | 2026-03-16 | |
| No filing history on record for this holder in this stock. | ||||||